PUMA
Istituto di Fisiologia Clinica     
Della Rossa A., Tavoni A., Merlini G., Baldini C., Sebastiani M., Lombardi M., Neglia D., Bombardieri S. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. In: Rheumatology (Oxford, England), vol. 44 (8) pp. 1074 - 1075. Oxford University Press, 2005.
 
 
Abstract
(English)
SIR, Takayasu arteritis (TA) is a chronic, idiopathic, inflammatory disease that primarily affects large vessels. The management of this disorder is largely unresolved, since a large number of patients fail to reach stable remission on conventional treatment. Thus, the need for more efficacious medical therapies is paramount in order to spare steroids and to prevent long-term toxicity and reduce disease-related morbidity and eventual mortality. Recently, Hofmann et al. have claimed the safety and efficacy of anti- tumour necrosis factor (TNF) therapy in an open label study in 15 patients with TA. Here we present two more cases of Takayasu arteritis treated with anti-TNF infliximab, in which clinical remission was observed.
Subject Takayasu Arteritis


Icona documento 1) Download Document PDF


Icona documento Open access Icona documento Restricted Icona documento Private

 


Per ulteriori informazioni, contattare: Librarian http://puma.isti.cnr.it

Valid HTML 4.0 Transitional